Skip to main content

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.

Publication ,  Journal Article
Thakar, MS; Broglie, L; Logan, B; Artz, A; Bunin, N; Burroughs, LM; Fretham, C; Jacobsohn, DA; Loren, AW; Kurtzberg, J; Martinez, CA ...
Published in: Blood
February 14, 2019

Despite improvements, mortality after allogeneic hematopoietic cell transplantation (HCT) for nonmalignant diseases remains a significant problem. We evaluated whether pre-HCT conditions defined by the HCT Comorbidity Index (HCT-CI) predict probability of posttransplant survival. Using the Center for International Blood and Marrow Transplant Research database, we identified 4083 patients with nonmalignant diseases transplanted between 2007 and 2014. Primary outcome was overall survival (OS) using the Kaplan-Meier method. Hazard ratios (HRs) were estimated by multivariable Cox regression models. Increasing HCT-CI scores translated to decreased 2-year OS of 82.7%, 80.3%, 74%, and 55.8% for patients with HCT-CI scores of 0, 1 to 2, 3 to 4, and ≥5, respectively, regardless of conditioning intensity. HCT-CI scores of 1 to 2 did not differ relative to scores of 0 (HR, 1.12 [95% CI, 0.93-1.34]), but HCT-CI of 3 to 4 and ≥5 posed significantly greater risks of mortality (HR, 1.33 [95% CI, 1.09-1.63]; and HR, 2.31 [95% CI, 1.79-2.96], respectively). The effect of HCT-CI differed by disease indication. Patients with acquired aplastic anemia, primary immune deficiencies, and congenital bone marrow failure syndromes with scores ≥3 had increased risk of death after HCT. However, higher HCT-CI scores among hemoglobinopathy patients did not increase mortality risk. In conclusion, this is the largest study to date reporting on patients with nonmalignant diseases demonstrating HCT-CI scores ≥3 that had inferior survival after HCT, except for patients with hemoglobinopathies. Our findings suggest that using the HCT-CI score, in addition to disease-specific factors, could be useful when developing treatment plans for nonmalignant diseases.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

February 14, 2019

Volume

133

Issue

7

Start / End Page

754 / 762

Location

United States

Related Subject Headings

  • Young Adult
  • Transplantation, Homologous
  • Transplantation Conditioning
  • Survival Rate
  • Prospective Studies
  • Prognosis
  • Metabolic Diseases
  • Male
  • Infant, Newborn
  • Infant
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thakar, M. S., Broglie, L., Logan, B., Artz, A., Bunin, N., Burroughs, L. M., … Sorror, M. L. (2019). The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. Blood, 133(7), 754–762. https://doi.org/10.1182/blood-2018-09-876284
Thakar, Monica S., Larisa Broglie, Brent Logan, Andrew Artz, Nancy Bunin, Lauri M. Burroughs, Caitrin Fretham, et al. “The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.Blood 133, no. 7 (February 14, 2019): 754–62. https://doi.org/10.1182/blood-2018-09-876284.
Thakar MS, Broglie L, Logan B, Artz A, Bunin N, Burroughs LM, et al. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. Blood. 2019 Feb 14;133(7):754–62.
Thakar, Monica S., et al. “The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.Blood, vol. 133, no. 7, Feb. 2019, pp. 754–62. Pubmed, doi:10.1182/blood-2018-09-876284.
Thakar MS, Broglie L, Logan B, Artz A, Bunin N, Burroughs LM, Fretham C, Jacobsohn DA, Loren AW, Kurtzberg J, Martinez CA, Mineishi S, Nelson AS, Woolfrey A, Pasquini MC, Sorror ML. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. Blood. 2019 Feb 14;133(7):754–762.

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

February 14, 2019

Volume

133

Issue

7

Start / End Page

754 / 762

Location

United States

Related Subject Headings

  • Young Adult
  • Transplantation, Homologous
  • Transplantation Conditioning
  • Survival Rate
  • Prospective Studies
  • Prognosis
  • Metabolic Diseases
  • Male
  • Infant, Newborn
  • Infant